TY  - JOUR 
AU  - Schmidt, W.A.
AU  - Dasgupta, B.
AU  - Sloane, J.
AU  - Giannelou, A.
AU  - Xu, Y.
AU  - Unizony, S.H.
AU  - Mackie, S.L.
AU  - González-Gay Mantecón, Miguel Ángel
AU  - Spiera, R.
AU  - Warrington, K.J.
AU  - Villiger, P.M.
AU  - Nivens, M.C.
AU  - Akinlade, B.
AU  - Lin, Y.
AU  - Buttgereit, F.
AU  - Stone, J.H.
PY  - 2023
SN  - 1478-6362
UR  - http://hdl.handle.net/20.500.11940/20994
AB  - Background: Giant cell arteritis (GCA) is primarily treated with glucocorticoids (GCs), which have substantial toxicity. Tocilizumab, an interleukin-6-receptor inhibitor (IL-6Ri), showed beneficial effects in GCA, leading to its approval. This study...
LA  - eng
KW  - Humans
KW  - Double-Blind Method
KW  - Giant Cell Arteritis
KW  - Treatment Outcome
KW  - COVID-19
KW  - COVID-19 Drug Treatment
TI  - A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
DO  - 10.1186/s13075-023-03177-6
T2  - Arthritis Research and Therapy
KW  - AS Santiago
KW  - CHUS
VL  - 25
ER  -